Lesinurad 400 mg plus febuxostat CROSS vs lesinurad 200 mg plus febuxostat CROSS
Mean sUA at end of 12 months · participants with tophi in gout
1 finding from 1 review
- no estimate extracted1 study · 67 participantsLow
Findings
What do systematic reviews say?
1,923 questions · 1,956 findings · 143 reviews · Musculoskeletal
No studies found 555 · 28.4%GRADE not reported 107 · 5.5%Very low 255 · 13%Low 555 · 28.4%Moderate 357 · 18.3%High 127 · 6.5%
Pegloticase every two weeks (biweekly) vs placebo
Quality of life ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Pegloticase every two weeks (biweekly) vs placebo
Serum urate normalisation ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Pegloticase every two weeks (biweekly) vs placebo
Function ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Pegloticase every two weeks (biweekly) vs placebo
Withdrawals due to adverse events · participants with tophi in gout
Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 7.59 [1.04, 55.55]1 study · 128 participantsModerate
Pegloticase every two weeks (biweekly) vs placebo
Total adverse events · participants with tophi in gout
Pegloticase every two weeks (biweekly) showed no clear difference in total adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.99 [0.91, 1.07]1 study · 128 participantsModerate
Monthly pegloticase vs placebo
Proportion with complete resolution of a target tophus · participants with tophi in gout
Monthly pegloticase showed no clear difference in proportion with complete resolution of tophi compared with placebo (moderate certainty).
1 finding from 1 review
- RR 2.86 [0.68, 11.97]1 study · 79 participantsModerate
Monthly pegloticase vs placebo
Joint pain reduction ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
NSAIDs vs placebo
Participant‐reported pain relief of 50% or greater · acute gout
NSAIDs may leads to higher pain: ≥ 50% improvement in pain (spontaneous pain at 24 hours) compared with placebo (low certainty).
1 finding from 1 review
- RR 2.75 [1.13, 6.72]Studies not reportedLow
Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors
Function: mean change in pain with movement from baseline on4‐point (0 to 3, 0 best function) Likert scale · acute gout
1 finding from 1 review
- no estimate extractedStudies not reportedLow
Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors
Global assessment of treatment success · acute gout
1 finding from 1 review
- no estimate extractedStudies not reportedModerate
Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors
Health‐related quality of life (mental) · acute gout
1 finding from 1 review
- no estimate extractedStudies not reportedLow
Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors
Withdrawals due to adverse events · acute gout
Non‐selective NSAIDs probably leads to higher withdrawals due to adverse events compared with selective cyclo‐oxygenase‐2 inhibitors (moderate certainty).
1 finding from 1 review
- RR 2.34 [1.33, 4.14]Studies not reportedModerate
Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors
Total adverse events · acute gout
Non‐selective NSAIDs probably leads to higher total adverse events compared with selective cyclo‐oxygenase‐2 inhibitors (moderate certainty).
1 finding from 1 review
- RR 1.94 [1.36, 2.78]Studies not reportedModerate
NSAIDs vs glucocorticoids
Pain: mean decrease per hour on a VAS scale (0 to 100, 0 no pain) · acute gout
1 finding from 1 review
- no estimate extractedStudies not reportedModerate
NSAIDs vs glucocorticoids
Swelling (mean) · acute gout
1 finding from 1 review
- no estimate extractedStudies not reportedLow
NSAIDs vs glucocorticoids
Function: walking disability during first 6 hours · acute gout
1 finding from 1 review
- no estimate extractedStudies not reportedModerate
NSAIDs vs glucocorticoids
Global assessment of treatment success · acute gout
NSAIDs showed no clear difference in patients' global assessment of treatment success at day 3 to 4 compared with glucocorticoids (moderate certainty).
1 finding from 1 review
- RR 0.92 [0.7, 1.22]Studies not reportedModerate
NSAIDs vs glucocorticoids
HRQOL ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
NSAIDs vs placebo
Inflammation: participants with no swelling at 72 hours (canakinumab 150 mg) Assessed by the investigator as no swelling, mild/palpable, moderate/visible, severe/bulging beyond the joint margins · acute gout
NSAIDs showed no clear difference in inflammation: swelling compared with placebo (low certainty).
1 finding from 1 review
- RR 1.08 [0.79, 1.49]Studies not reportedLow